Improved pharmaceutical stability of a boronphenylalanine mannitol formulation for boron neutron capture therapyHalbert Gavin, Elliott Moira, Ford Steven, Dick Lindsay, Schmidt ElkeEuropean Journal of Pharmaceutical Sciences Vol 48, pp. 735-739, (2013)http://dx.doi.org/10.1016/j.ejps.2013.01.008 Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for phase I clinical trialElliott Moira, Ford S J, Prasad E, Dick L J, Farmer H, Hogg P J, Halbert G WInternational Journal of Pharmaceutics Vol 426, pp. 67-75, (2012)http://dx.doi.org/10.1016/j.ijpharm.2012.01.024 Experimental scrutiny and project timelines : an exampleDooley N., Ford S. J., Prasad Elke, Elliott M., Halbert GavinJournal of Pharmacy and Pharmacology Vol 62, pp. 1208-1209, (2010)http://dx.doi.org/10.1111/j.2042-7158.2010.01178.x Effects of substituting Fructose by Mannitol in a pharmaceutical formulationSchmidt E., Ford S., Dooley N., Elliot M., Halbert G.Journal of Pharmacy and Pharmacology Vol 62, pp. 1428-1429, (2010)http://dx.doi.org/10.1111/j.2042-7158.2010.01178.x